Aromatase Inhibitor Brain Study

STUDY BASICS

Are you a postmenopausal woman with non-metastatic breast cancer (cancer that has not spread to another part of the body) who is planning to receive aromatase inhibitor therapy? If so, you may be able to participate in a research study to better understand the way the brain works in women who take aromatase inhibitors. Participants will be compensated.

STUDY PURPOSE

Aromatase inhibitors are drugs that block your body’s ability to make estrogen, and are commonly used to treat postmenopausal women with breast cancer. Examples of aromatase inhibitors approved by the FDA are anastrozole (Arimidex®), letrozole (Femara®), and exemestane (Aromasin®). The purpose of this study is to help researchers understand the way the brain works in women who take aromatase inhibitors for non-metastatic breast cancer therapy.

COULD THIS STUDY BE RIGHT FOR YOU?

• Postmenopausal
• Diagnosed with non-metastatic breast cancer (cancer that has not spread to another part of the body)
• Will receive anastrozole/Arimidex® (but have not already started)
• Have not and do not plan to receive chemotherapy
• Willing and able to undergo MRI scan

WHAT PARTICIPANTS CAN EXPECT

Participation involves three study visits over approximately 18 months, in which participants will complete tasks while lying in a MRI scanner, answer questions about mental function and mood, and have blood drawn.